Last updated on October 2018

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Brief description of study

The trial objective is to demonstrate the safety of idarucizumab, as assessed by the occurence of patients with drug related adverse events (including immune reactions) and all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in ongoing clinical trials who require emergency surgery/urgent procedures or patients who have life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid reversal of the anticoalugant effect of dabigatran is needed.

Clinical Study Identifier: NCT02815670

Contact Investigators or Research Sites near you

Start Over

Boehringer Ingelheim Call Center

St. Petersburg State Pediatric University
St. Petersburg, Russian Federation
  Connect »